Abstract 251P
Background
Uterine leiomyoma (UL) is the most common female pelvic benign tumor with recurrence rates of 16.7%-52.8%. We aimed to propose a prognostic index (PI) model for predicting the long-term (>5 years) risk of UL recurrence.
Methods
Women aged 18–44 years who initially underwent myomectomy for UL at one of the three study hospitals between April 2012 and October 2013 were enrolled. The data collected included patients’ demographics, leiomyomas’ characteristics, relapses, subsequent contraceptive methods, and postoperative gravidity and parity. A PI model was proposed based on the β-coefficients in the results of multivariate Cox regression analysis in prediction model group. The differences among the PI-based risk groups were tested by Kaplan–Meier analysis (using paired log-rank test) and univariate Cox regression analysis (using the Forward: LR) in prediction model, internal validation and external validation group.
Results
There were 725 patients included in this study. PI formula =1.5(if 3-5 leiomyomas)+2(if > 5 leiomyomas)+1(if residue)+1(if not submucosal)+1(if combined endometriosis). The PI value (0-5) was divided into low-risk group, intermediate-risk group, and high-risk group by cut-off values 1.25 and 3.75. In the prediction model group, the high-risk group had a significantly 4.55 times greater recurrence risk of UL than that in the low-risk group [cumulative recurrence rate (CR): 82.1% vs 29.5%, HR = 4.55, 95% CI; 2.821-7.339]; the intermediate-risk group had a significantly 2.81 times greater recurrence risk of UL than that in the low-risk group (CR: 62.3% vs 29.5%, HR = 2.81, 95% CI; 2.035-3.878). The differences between any two risk groups were also statistically significant (P < 0.05) in both internal and external validation groups.
Conclusions
The PI model was proved to be effective in distinguishing low-risk, intermediate-risk, and high-risk groups for long-term recurrence of UL after initial myomectomy in women aged 18-44 years, allowing it to be an objective tool aid in clinical decision making. In the future, prospective researches should be carried out to confirm the predictive ability of this PI model, and its practical value in clinical decision making.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Zheng Yu Li.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
205P - Treatment pattern and outcomes of radium-223 (Ra223) in metastatic castration resistant prostate cancer (mCRPC): Retrospective cohort analysis from Hong Kong
Presenter: Darren Poon
Session: Poster display session
Resources:
Abstract
206P - Population-based validation of the risk stratification among prostate cancer patients
Presenter: Mu Xie
Session: Poster display session
Resources:
Abstract
211P - Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
Presenter: Chi Fai Ng
Session: Poster display session
Resources:
Abstract
212P - Immunotherapy with nivolumab in metastatic renal cell carcinoma patients in India: Bringing a change in clinical practice
Presenter: Amit Rauthan
Session: Poster display session
Resources:
Abstract
213P - An observational retrospective real-world study of sarcomatoid renal cell carcinoma (sRCC) patients in an Asian cancer centre
Presenter: Ravindran Kanesvaran
Session: Poster display session
Resources:
Abstract
214P - Targeting epithelial-mesenchymal transition (EMT), novel strategy to delay resistance or re-sensitize renal cancer to Sunitinib
Presenter: Revati Sharma
Session: Poster display session
Resources:
Abstract
215P - Radiologic and pathologic tumour size variation in localized renal cell carcinoma and its implications
Presenter: Shanky Singh
Session: Poster display session
Resources:
Abstract
216P - Partial versus radical nephrectomy: 10- year long-term survival among patients with Wilms tumour
Presenter: Mira Mostafa
Session: Poster display session
Resources:
Abstract
217P - Neutrophil-to-lymphocyte ratio is a useful biomarker for predicting worse clinical outcome in chemo-resistant urothelial carcinoma patients treated with pembrolizumab
Presenter: Koichiro Ogihara
Session: Poster display session
Resources:
Abstract
219P - Long-term outcomes of bladder preservation in muscle-invasive bladder cancer patients
Presenter: Amanda Dania Satiti
Session: Poster display session
Resources:
Abstract